Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04089449 · ClinicalTrials.gov registry record · Phase 1

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

A Phase 1 study of Advanced Solid Tumor and Recurrent Glioma, sponsored by Prelude Therapeutics.

Completed
Registry status
Phase 1
Development phase
86
Enrollment target
11
Study locations

NCT04089449 is a Phase 1 study of Advanced Solid Tumor and Recurrent Glioma that has completed, run by Prelude Therapeutics. The registered enrollment target is 86 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04089449, a Phase 1 study of Advanced Solid Tumor and Recurrent Glioma, has completed, sponsored by Prelude Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
86 participants
Enrollment target
11
Study locations

Study Summary

This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.

Conditions Studied

Advanced Solid Tumor Recurrent Glioma

Interventions

  • DRUG PRT811

Study Locations (11)

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Connecticut

  • Yale- New Haven Hospital- Yale Cancer Center - New Haven

Delaware

  • Christiana Care Health Services, Christiana Hospital - Newark

Florida

  • Florida Cancer Specialists - Lake Mary

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Illinois

  • Northwestern Memorial Hospital - Chicago

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Missouri

  • Washington University School of Medicine - Siteman Cancer Center - St Louis

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2019-11-06
Est. Completion 2023-03-28
Phase Phase 1

Sponsor

Prelude Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04089449

The ClinicalTrials.gov registry entry for NCT04089449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PRT811 is the first listed.

NCT04089449 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Colorado, Connecticut, Delaware.

Frequently Asked Questions

What is clinical trial NCT04089449 about?

NCT04089449 is a clinical study titled "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas". This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequ...

What is the current status of trial NCT04089449?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2019-11-06. Estimated completion is 2023-03-28.

What conditions does trial NCT04089449 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Recurrent Glioma.

What interventions are being tested in trial NCT04089449?

The interventions under investigation include: PRT811 (DRUG).

Who is sponsoring clinical trial NCT04089449?

This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04089449 being conducted?

This trial has 11 study locations across Colorado, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Recurrent Glioma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.